RADVAX: Nivolumab / ipilimumab with SBRT for metastatic renal cell carcinoma

Bookmark and Share
Published: 19 Feb 2020
Views: 904
Dr Hans Hammers - UT Southwestern Medical Center, Dallas, USA

Dr Hans Hammers speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the RADVAX trial for kidney cancer.

RADVAX looks to combine standard of care ICI (nivolumab/ipilimumab) with high dose stereotactic radiation to increase the response rate.

The results look promising, but the study is small, so Dr Hammers hopes to see if these results hold up against a larger cohort.